Metropolitan Life Insurance Company (MetLife)’s Enanta Pharmaceuticals ENTA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,114	Closed	-$19.4K	–	673
2024 Q1	$19.4K	Hold	1,114	–	–	﹤0.01%	1879
2023 Q4	$10.5K	Hold	1,114	–	–	﹤0.01%	2164
2023 Q3	$12.4K	Hold	1,114	–	–	﹤0.01%	2125
2023 Q2	$23.8K	Hold	1,114	–	–	﹤0.01%	1837
2023 Q1	$45K	Sell	1,114 -159	-12%	-$7.59K	﹤0.01%	1442
2022 Q4	$59.2K	Hold	1,273	–	–	﹤0.01%	1361
2022 Q3	$66K	Hold	1,273	–	–	﹤0.01%	1275
2022 Q2	$60.2K	Hold	1,273	–	–	﹤0.01%	1381
2022 Q1	$90.6K	Sell	1,273 -4,139	-76%	-$269K	﹤0.01%	1257
2021 Q4	$405K	Hold	5,412	–	–	0.01%	1562
2021 Q3	$307K	Buy	5,412 +100	+2%	+$4.94K	﹤0.01%	1754
2021 Q2	$234K	Sell	5,312 -1	-0%	-$49	﹤0.01%	2034
2021 Q1	$262K	Hold	5,313	–	–	﹤0.01%	1829
2020 Q4	$224K	Hold	5,313	–	–	﹤0.01%	1865
2020 Q3	$243K	Sell	5,313 -1,262	-19%	-$61.1K	﹤0.01%	1661
2020 Q2	$330K	Buy	6,575 +893	+16%	+$46.2K	0.01%	1488
2020 Q1	$292K	Buy	5,682 +208	+4%	+$11.1K	0.01%	1369
2019 Q4	$338K	Hold	5,474	–	–	0.01%	1564
2019 Q3	$329K	Hold	5,474	–	–	0.01%	1547
2019 Q2	$462K	Hold	5,474	–	–	0.01%	1354
2019 Q1	$523K	Hold	5,474	–	–	0.01%	1267
2018 Q4	$388K	Hold	5,474	–	–	0.01%	1365
2018 Q3	$468K	Hold	5,474	–	–	0.01%	1422
2018 Q2	$634K	Buy	5,474 +472	+9%	+$47.1K	0.01%	1159
2018 Q1	$405K	Hold	5,002	–	–	0.01%	1414
2017 Q4	$294K	Sell	5,002 -5,640	-53%	-$282K	﹤0.01%	1634
2017 Q3	$498K	Sell	10,642 -1,018	-9%	-$40.9K	﹤0.01%	1693
2017 Q2	$420K	Hold	11,660	–	–	﹤0.01%	1829
2017 Q1	$359K	Hold	11,660	–	–	﹤0.01%	1883
2016 Q4	$391K	Hold	11,660	–	–	﹤0.01%	1892
2016 Q3	$310K	Hold	11,660	–	–	﹤0.01%	2046
2016 Q2	$257K	Hold	11,660	–	–	﹤0.01%	2146
2016 Q1	$342K	Hold	11,660	–	–	﹤0.01%	1816
2015 Q4	$385K	Hold	11,660	–	–	﹤0.01%	1802
2015 Q3	$421K	Buy	11,660 +335	+3%	+$14.4K	﹤0.01%	1750
2015 Q2	$510K	Buy	11,325 +3,103	+38%	+$121K	﹤0.01%	1730
2015 Q1	$252K	Hold	8,222	–	–	﹤0.01%	1932
2014 Q4	$418K	Hold	8,222	–	–	﹤0.01%	1894
2014 Q3	$325K	Hold	8,222	–	–	﹤0.01%	2016
2014 Q2	$354K	Buy	+8,222	New	+$314K	﹤0.01%	2074

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ENTA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Enanta Pharmaceuticals (ENTA) in Q2 2024, closing a stake of 1,114 shares — an estimated $19.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ENTA in Q2 2014 and held it in 40 quarters. The position peaked at $634K in Q2 2018. 101 funds tracked by Wall St. Rank hold ENTA as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Enanta Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,114 Enanta Pharmaceuticals shares in Q2 2024, an estimated $19.4K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 40 quarters.
Metropolitan Life Insurance Company (MetLife)'s Enanta Pharmaceuticals position peaked at $634K in Q2 2018.
101 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.